Halozyme Therapeutics HALO Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's return on assets?
- Halozyme Therapeutics (HALO) reported return on assets of 27.4% in Q3 2025.
- How has Halozyme Therapeutics's return on assets changed year-over-year?
- Halozyme Therapeutics's return on assets increased by 40.2% year-over-year, from 19.6% to 27.4%.
- What is the long-term trend for Halozyme Therapeutics's return on assets?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's return on assets has grown at a 0.9% compound annual growth rate (CAGR), from 22.5% to 23.4%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.